Clinical trials: Lung Cancer Stage I
Non-Small Cell Lung Cancer
Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)
This study will treat patients with advanced NSCLC harboring EGFR mutations. This is the first study to test DZD6008 combined with sunvozertinib in patients, which will help to understand what type of side effects with the…
- Trial name
- NCT07079475
- Testing
- DZD6008, Sunvozertinib, Osimertinib
- Where
- 14 sites in China
- Volunteers
- 220 people
- Sponsor
- Dizal Pharmaceuticals
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
This study evaluates the use of SMS001 in patients with lung cancer. SMS001 is a new form of drug Paclitaxel. Doctors want to decide an appropriate safe dose for SMS001 administration, and to see how well it works in treating…
- Trial name
- NCT06693336
- Testing
- SMS001
- Where
- 2 sites in United States, Canada
- Volunteers
- 42 people
- Sponsor
- ToLymph Inc.
Small Cell Lung Cancer and Breast Cancer
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
This study consists of two phases. The phase I study is designed to investigate the safety and tolerability of Satoreotide tetraxetan following fractionated i.v.
- Trial name
- SSTR2+ (NCT03773133)
- Testing
- Satoreotide tetraxetan, Satoreotide trizoxetan
- Where
- 8 sites in United States, Austria and 5 more
- Volunteers
- 9 people
- Sponsor
- Ipsen
Advanced Malignancies, Non-small Cell Lung Cancer
A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer
The main purpose of this study is to assess the safety profile of MGCD265 when administered in combination with the marketed anticancer drugs erlotinib and docetaxel.
- Trial name
- NCT00975767
- Testing
- MGCD265+erlotinib, MGCD265+docetaxel
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- Mirati Therapeutics Inc.
Gastrointestinal Cancer, Lung Cancer
A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Advanced Cancer (Solid Tumours) Positive for B7-H6
This is a study in adults from Asia with different types of advanced cancer (solid tumours). People can join the study if they have cancer of the stomach, large bowel and rectum, pancreas, liver, head and neck or non-small cell…
- Conditions
- Gastrointestinal Cancer, Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT06091930
- Testing
- BI 765049, Ezabenlimab
- Where
- 3 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Boehringer Ingelheim
Non-Small Cell Lung Cancer
Feasibility Study of Pemetrexed in Combination With Cisplatin or Carboplatin as Adjuvant Treatment of Non-Small Cell Lung Cancer
This study is a multicenter, open-label, two-arm, randomized, parallel Phase 2 feasibility study of pemetrexed in combination with either cisplatin (Arm A) or carboplatin (Arm B) as adjuvant combination-chemotherapy in…
- Trial name
- NCT00269152
- Testing
- pemetrexed, cisplatin, carboplatin
- Where
- 18 sites in France, Germany and 1 more
- Volunteers
- 122 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
A Phase I/IIa Study of UV1 Vaccination in Patients With Non Small Cell Lung Cancer.
In this study, up to 21 patients with lung cancer will receive UV1 (a therapeutic synthetic peptide vaccine) at different dose levels. The safety and tolerability of UV1 as well as immunological response will be assessed.
- Trial name
- UV1-hTERT2012L (NCT01789099)
- Testing
- UV1 synthetic peptide vaccine and GM-CSF
- Where
- Norway
- Volunteers
- 18 people
- Sponsor
- Ultimovacs ASA
EGFR Gene Mutation
Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC
YH25448 is an oral, highly potent, mutant-selective and irreversible EGFR Tyrosine-kinase inhibitors (TKIs) targets both the T790M mutation and activating EGFR mutations while sparing wild type-EGFR.
- Trial name
- NCT03046992
- Testing
- YH25448
- Where
- 16 sites in South Korea
- Volunteers
- 224 people
- Sponsor
- Yuhan Corporation
Lung Cancer, Non-Small Cell
NSCLC Burden of Illness Study
The aim of this observational study is to identify and quantify the humanistic and economic burden of illness of patients with complete resection (no residual disease) of stage IB-IIIA NSCLC in three European countries (France…
- Trial name
- LuCaBIS (NCT01772225)
- Testing
- Data collection
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer
First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours
The purpose of this study is to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of AZD8701 Alone and in Combination with Durvalumab (MEDI4736) in Adult Subjects with…
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck
- Trial name
- NCT04504669
- Testing
- AZD8701, Durvalumab
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
HER2-expressing Cancers
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
This is a first-in-human, 3-part study to investigate the safety, tolerability, and effectiveness of ZW25 (zanidatamab) by itself and combined with selected chemotherapy agents in patients with locally advanced (unresectable)…
- Trial name
- NCT02892123
- Testing
- ZW25 (Zanidatamab), Paclitaxel, Capecitabine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 279 people
- Sponsor
- Jazz Pharmaceuticals
NSCLC
A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation
This is a consolidation therapy trial evaluating GI-4000 in subjects with NSCLC treated with curative intent who are disease free at their first post-treatment restaging assessment.
- Trial name
- NCT00655161
- Testing
- GI-4000
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- GlobeImmune
Advanced Breast Cancer, Advanced Carcinomas With Squamous Cell Histology
A Phase I Study of BKM120 in Adult Chinese Patients With Advanced Solid Tumors
Dose escalation study with a dose expansion phase, to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy of two dose levels of BKM120 when administered orally.
- Trial name
- NCT01626209
- Testing
- BKM120
- Where
- 3 sites in China
- Volunteers
- 32 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Non Small Cell Lung Cancer (NSCLC)
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the effect of food on the pharmacokinetics (PK) of the experimental drug, entinostat, in women with breast cancer and men and women with non-small cell lung cancer.
- Conditions
- Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
- Trial name
- ENCORE110 (NCT01594398)
- Testing
- entinostat, Erlotinib, Exemestane
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Syndax Pharmaceuticals
Non-small Cell Carcinoma, Adenocarcinoma of Lung
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
This 2-phase study will determine the safety of treating patients with non-small cell lung cancer with the genetically engineered HyperAcute-Lung cancer vaccine.
- Conditions
- Non-small Cell Carcinoma, Adenocarcinoma of Lung, Squamous Cell Carcinoma, Large Cell Carcinoma
- Trial name
- NCT00073398
- Testing
- Drug: Hyperacute Lung Cancer Cell Vaccine
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- NewLink Genetics Corporation
Solid Tumor, Gynecologic Cancer
A Study of GC203 TIL in Advanced Malignant Solid Tumors
A clinical trial to assess the safety and efficacy of engineered Tumor Infiltrating Lymphocytes (TIL) for the treatment of Advanced Malignant Solid Tumors
- Conditions
- Solid Tumor, Gynecologic Cancer, Breast Cancer, Gastrointestinal Cancer
- Trial name
- KUNLUN-001 (NCT06375187)
- Testing
- Engineering Tumor Infiltrating Lymphocytes
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Juncell Therapeutics
Epithelial Ovarian Cancer, Gastric Adenocarcinoma
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies.
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
- Trial name
- MK-2870-001 (NCT04152499)
- Testing
- SKB264
- Where
- 109 sites in United States, Canada and 4 more
- Volunteers
- 1,410 people
- Sponsor
- Klus Pharma Inc.
Neoplasms, Carcinoma, Non-Small-Cell Lung
This Study Tests the New Medicine BI 754111 Alone or in Combination With Another New Substance BI 754091 in Patients With Advanced Cancer. The Study Tests Different Doses to Find the Best Dose for Continuous Treatment.
This is a study in adults with advanced solid tumors including non-small cell lung cancer. The study tests the combination of two medicines called BI 754111 and BI 754091 that may help the immune system to fight the cancer.
- Trial name
- NCT03156114
- Testing
- Ezabenlimab, BI 754111
- Where
- 15 sites in United States, Canada and 3 more
- Volunteers
- 172 people
- Sponsor
- Boehringer Ingelheim
Lung Cancer
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
This study is to assess the safety and tolerability of Cediranib (RECENTIN™, AZD2171)in combination with etoposide and cisplatin (EP) as first line treatment for lung cancer patients with extensive stage or metastatic disease for…
- Trial name
- NCT00621361
- Testing
- AZD2171, Etoposide, Cisplatin
- Where
- 4 sites in United States
- Volunteers
- 62 people
- Sponsor
- AstraZeneca
Advanced Cancer, Advanced Solid Tumor
A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients
The study comprises two phases: phase I dose escalation (including PK run-in period and treatment period) and phase II study.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell
- Trial name
- NCT04237805
- Testing
- SAF-189s
- Where
- 41 sites in China
- Volunteers
- 280 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.